A PHASE IV, MULTICENTER, OPEN-LABEL STUDY OF THE IMMUNOGENICITY OF NUTROPIN AQ V1.1 [SOMATROPIN (rDNA ORIGIN) INJECTION] ADMINISTERED DAILY TO NA??VE GROWTH HORMONEDEFICIENT CHILDREN
|Effective start/end date||1/1/15 → 12/31/18|
- GENENTECH, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.